Conserved domains and structure prediction of human cytomegalovirus UL27 protein

Antiviral Therapy

Volumn 14, Issue 5, 2009, Pages 663-672

  Hantz, Sébastien ^a   Couvreaux, Anthony ^b   Champier, Gaël ^a   Trapes, Laurène ^a   Cotin, Sébastien ^a   Denis, François ^a   Bouaziz, Serge ^b   Alain, Sophie ^a  

^a UNIVERSITY OF LIMOGES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAVIR; CYTOMEGALOVIRUS UL27 PROTEIN; GANCICLOVIR; NUCLEAR PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DNA POLYMORPHISM; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; SEQUENCE ANALYSIS; VIRUS REPLICATION; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CONSERVED SEQUENCE; CYTOMEGALOVIRUS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RIBONUCLEOSIDES; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 69849093080     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Chulay Biron K, Wang L, et al. Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease. Adv Exp Med Biol 1999; 458:129-134.
2. Biron KK, Harvey RJ, Chamberlain SC et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-ribonucleoside with a unique mode of action. Antimicrob Agents Chemother 2002; 46:2365-2372.
3. Evers DL, Komazin G, Ptak RG, et al. Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms. Antimicrob Agents Chemother 2004; 48:3918-3927.
4. Winston DJ, Young JAH, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in a logeneic stem cell transplant recipients. a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008; 111:5403-5410.
5. Krosky PM, Baek MC, Coen DM. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J Virol 2003; 77:905-914.
6. Krosky PM, Baek MC, Jahng WJ, et al. The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. J Virol 2003; 77:7720-7727.
7. Prichard MN, Britt WJ, Daily SL, Hartline CB, Kern ER. Human cytomegalovirus UL97 kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis. J Virol 2005; 79:15494-15502.
8. Komazin G, Ptak RG, Emmer BT, Townsend LB, Drach JC. Resistance of human cytomegalovirus to the-benzimidazole L-ribonucleoside maribavir maps to UL27. J Virol 2003; 77:11499-11506.
9. Chou S, Marousek GI, Senters AE, Davis MG, Biron KK. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J Virol 2004; 78:7124-7130.
10. Chou S. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. Antimicrob Agents Chemother 2009; 53:81-85.
11. Chou S, Wechel LC, Marousek GI. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J Infect Dis 2007; 196:91-94.
12. Ducancelle A, Belloc S, Alain S, et al. Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy. J Clin Virol 2004; 29: 241-247.
13. Hirt B. Selective extraction of polyoma DNA from infected mouse cell culture. J Mol Biol 1967; 26:365-369.
14. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, positions-specific gap penalties an weight matrix choice. Nucleic Acids Res 1994; 22:4673-4680.
15. McGeoch DJ, Rixon FJ, Davison AJ. Topics in herpesvirus genomics and evolution. Virus Res 2006; 117:90-104.
16. Taylor WR. The classification of amino acid conservation. J Theor Biol 1986; 119:205-218.
17. Ansari S, Helms V. Statistical analysis of predominantly transient protein-protein interfaces. Proteins 2005; 61:344-355.
18. Bogan AA, Thorn KS. Anatomy of hot spots in protein interfaces. J Mol Biol 1998; 280:1-9.
19. Ofran Y, Rost B. Analysing six types of protein-protein interfaces. J Mol Biol 2003; 325:377-387.
20. Glaser F, Steinberg DM, Vakser IA, Ben-Tal N. Residue frequencies and pairing preferences at protein-protein interfaces. Proteins 2001; 43:89-102.
21. Larder BA, Kemp SD, Darby G. Related functional domains in virus DNA polymerases. EMBO J 1987; 6:169-175.
22. Shi R, Azzi A, Gilbert C, Boivin G, Lin SX. Three-dimensional modeling of cytomegalovirus DNA polymerase and preliminary analysis of drug resistance. Proteins 2006; 64:301-307.
23. Champier G, Couvreux A, Hantz S, et al. Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. Antivir Ther 2008; 13:643-654.
24. Champier G, Hantz S, Couvreux A, et al. New functional domains of human cytomegalovirus pUL89 predicted b sequence analysis and three-dimensional modelling of the catalytic site DEXDc. Antivir Ther 2007; 12:217-232.
25. Baek MC, Krosky PM, He Z, Coen DM. Specific phosphorylation of exogenous protein and peptide substrates by the human cytomegalovirus UL97 protein kinase. Importance of the P+5 position. J Biol Chem 2002; 277:29593-29599.
26. Dolan A, Cunningham C, Hector RD, et al. Genetic content of wild-type human cytomegalovirus. J Gen Virol 2004; 85:1301-1312.